Testing must also be done to ensure there are no rearrangements involving platelet‐derived growth factor A (PDGFRA), PDGFRB, fibroblast growth factor receptor 1 (FGFR1), or pericentriolar material 1 (PCM1)‐Janus kinase 2 (JAK2) fusions in patients with eosinophilia to exclude this group of myeloid neoplasms [1]. The gene discussed is FGFR1; the disease is Increased total eosinophil count.